Lauren Pischel, MD, MSc
Instructor of Medicine (Infectious Diseases)DownloadHi-Res Photo
Cards
Appointments
Infectious Diseases
Primary
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
Appointments
Infectious Diseases
Primary
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
Appointments
Infectious Diseases
Primary
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
About
Titles
Instructor of Medicine (Infectious Diseases)
Affiliated Faculty, Yale Institute for Global Health
Biography
Dr. Lauren Pischel obtained her undergraduate degree in biology at Brown University and worked in the lab of Dr. Jake Kurtis on the development of a pediatric malaria vaccine. She obtained her MD at Stanford where she conducted research with Dr. Julie Parsonnet on the impact of an antimicrobial triclosan on the human microbiome. She then completed her internal medicine residency at Yale where she was awarded the primary care award for the Fair Haven Community Health Center. She subsequently pursued here fellowship in infectious diseases at Yale and her Master of Science in the epidemiology of infectious diseases at Yale. Her current interests include the epidemiology and household transmission of COVID-19 and influenza as well vaccine effectiveness and emerging infectious diseases, as well as interactions of infectious diseases with climate change and changing environmental landscapes.
Appointments
Infectious Diseases
InstructorPrimary
Other Departments & Organizations
Education & Training
- MSc
- Yale, Public Health- Epidmiology of Infectious Diseases (2022)
- MD
- Stanford School of Medicine (2016)
- ScB
- Brown University, Biology (2011)
Research
Overview
Public Health Interests
Emerging Infectious Diseases; Global Health; Climate Change; Vaccines
ORCID
0000-0002-7697-0084
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lauren Pischel's published research.
Publications Timeline
A big-picture view of Lauren Pischel's research output by year.
Kavin Patel
George Goshua, MD, MSc, FACP
Richard A Martinello, MD
Albert Ko, MD
Alfred Lee, MD, PhD
Lydia Aoun-Barakat, MD
26Publications
338Citations
Publications
2024
Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis
Pischel L, Martini B, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel K, Grimshaw A, Malik A, Goshua G, Omer S. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 2024, 42: 126053. PMID: 38906763, DOI: 10.1016/j.vaccine.2024.06.021.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPost-exposure prophylaxisMVA-BNVaccine effectivenessMeta-analysisTime of administrationNewcastle-Ottawa ScaleRisk of publication biasMeasuring vaccine efficacyImmortal time biasImmunogenicity studiesNewcastle-OttawaWeb of ScienceVaccine efficacyAnimal studiesEgger's testDisease severityFunnel plotPrimary searchDosePublication biasStudy qualityVaccineSystematic reviewVaccination timingMpox outbreakCharacterizing healthcare personnel attitudes toward receipt of a voluntary bivalent COVID-19 booster vaccine during a COVID-19 outbreak at a behavioral health hospital in Connecticut
Roberts S, Willebrand K, Fredrick J, Pischel L, Patel K, Murray T, Martinello R. Characterizing healthcare personnel attitudes toward receipt of a voluntary bivalent COVID-19 booster vaccine during a COVID-19 outbreak at a behavioral health hospital in Connecticut. Antimicrobial Stewardship & Healthcare Epidemiology 2024, 4: e87. PMID: 38774120, PMCID: PMC11106727, DOI: 10.1017/ash.2024.78.Peer-Reviewed Original ResearchAltmetric
2023
Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster
Willebrand K, Fredrick J, Pischel L, Patel K, Roberts S, Murray T, Martinello R. Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster. Antimicrobial Stewardship & Healthcare Epidemiology 2023, 3: s56-s57. PMCID: PMC10594485, DOI: 10.1017/ash.2023.300.Peer-Reviewed Original ResearchConceptsBooster doseBehavioral health unitHealthcare workersHealth unitsCOVID-19COVID-19 outbreakInpatient behavioral health unitFirst booster dosePrimary vaccination seriesCOVID-19 vaccinationCOVID-19 exposureBehavioral health settingsMonovalent vaccinationVaccination seriesBooster dosesBooster vaccineComplete responsePrevious vaccinationVaccine uptakeHealth HospitalGeneral populationSide effectsPsychiatric hospitalHealth settingsDemographic data
2022
Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population
Zhao M, Slotkin R, Sheth AH, Pischel L, Kyriakides TC, Emu B, McNamara C, Shi Q, Delgobbo J, Xu J, Marhoffer E, Mercer-Falkoff A, Holleck J, Ardito D, Sutton RE, Gupta S. Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population. Clinical Infectious Diseases 2022, 76: e391-e399. PMID: 35639598, PMCID: PMC9278145, DOI: 10.1093/cid/ciac416.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMonth postboosterRNA vaccinationClinical variablesNeutralization responseEnd-stage renal diseaseBooster dose responsePrimary series vaccinationPrimary vaccine seriesMultiple clinical factorsSystemic steroid useDoses of vaccinePrior COVID-19Maximal inhibitory concentration valuesHalf maximal inhibitory concentration (IC50) valuesSeries vaccinationVaccine seriesVaccine regimensClinical factorsDiabetes mellitusRenal diseaseComorbid conditionsSteroid useCOVID infectionImmune responseUS populationRainfall and other meteorological factors as drivers of urban transmission of leptospirosis
Cunha M, Costa F, Ribeiro GS, Carvalho MS, Reis RB, Nery N, Pischel L, Gouveia EL, Santos AC, Queiroz A, Wunder EA, Reis MG, Diggle PJ, Ko AI. Rainfall and other meteorological factors as drivers of urban transmission of leptospirosis. PLOS Neglected Tropical Diseases 2022, 16: e0007507. PMID: 35404948, PMCID: PMC9022820, DOI: 10.1371/journal.pntd.0007507.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsCost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican SocietyAdenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis
Pischel L, Patel KM, Goshua G, Omer SB. Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2022, 75: 1179-1186. PMID: 35134164, PMCID: PMC9383370, DOI: 10.1093/cid/ciac080.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdenovirus-vectored vaccinePregnant womenVector vaccinesSystematic reviewGeneral populationAdenovirus vector-based vaccinesClinical trial populationsVector-based vaccinesCrucial risk factorVaccine recipientsHypercoagulable stateTrial populationRisk factorsClinical trialsJohnson vaccineRare caseVaccine componentsThrombocytopeniaVaxzevria vaccineMeta-AnalysisVaccine developmentVaccinePotential associationCoagulopathyInfectious diseasesA review of COVID-19 transmission dynamics and clinical outcomes on cruise ships worldwide, January to October 2020
Willebrand KS, Pischel L, Malik AA, Jenness SM, Omer SB. A review of COVID-19 transmission dynamics and clinical outcomes on cruise ships worldwide, January to October 2020. Eurosurveillance 2022, 27: 2002113. PMID: 34991781, PMCID: PMC8739343, DOI: 10.2807/1560-7917.es.2022.27.1.2002113.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 casesCOVID-19COVID-19-associated deathsAttack rateMedian attack rateCOVID-19 outbreakUnited States CentersSARS-CoV-2Mean attack rateClinical outcomesMedian numberCOVID-19 transmission dynamicsEpidemiological informationDisease controlDiamond PrincessSuperspreader eventsStates CentersSusceptible populationTransmission dynamicsPrevention's listOutbreakInternational spread
2021
386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020
Willebrand K, Pischel L, Malik A, Jenness S, Omer S. 386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020. Open Forum Infectious Diseases 2021, 8: 294-295. PMCID: PMC8644941, DOI: 10.1093/ofid/ofab466.587.Peer-Reviewed Original ResearchConceptsCOVID-19 casesCOVID-19Systematic reviewAttack rateMedian attack rateSARS-CoV-2Full-text articlesMean attack rateClinical responseMedian numberCOVID-19 transmission dynamicsEpidemiologic informationNumber of casesPRIMSA guidelinesDisease controlFinal analysisDiamond PrincessText articlesCOVID-19 outbreakSusceptible populationTransmission dynamicsMEDLINEOutbreakInternational spreadPercent572. Real-world Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in a Retrospective Cohort
Vahidy F, Pischel L, Tano M, Pan A, Boom M, Sostman H, Nasir K, Omer S. 572. Real-world Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in a Retrospective Cohort. Open Forum Infectious Diseases 2021, 8: 388-388. PMCID: PMC8644874, DOI: 10.1093/ofid/ofab466.770.Peer-Reviewed Original ResearchCitationsConceptsCOVID-19 mRNA vaccinesVaccine effectivenessImmunization statusMRNA vaccinesDose groupRetrospective cohortSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinesSARS-CoV-2 mRNA vaccinesCOVID-19 related hospitalizationsCox proportional hazards modelDiverse US cohortCharlson Comorbidity IndexReal-world effectivenessProportional hazards modelCOVID-19 hospitalizationCOVID-19 mortalityArea Deprivation IndexHealth care systemMore comorbiditiesComorbidity indexRelated hospitalizationsCohort enrollmentUS cohortClinical trialsOdds ratio
Academic Achievements & Community Involvement
honor Janeway Society Member
Yale School of Medicine AwardDetails10/10/2024
News
News
- July 27, 2022
New Appointments & Promotions Within Department of Internal Medicine
- April 14, 2022
Discoveries & Impact (April 2022)
- December 02, 2020
Infectious Disease Fellowship Supports Doctor’s Research
- March 30, 2020Source: Health
What is PPE? Everything You Need to Know About Personal Protective Equipment Amid the Coronavirus Outbreak